233 related articles for article (PubMed ID: 24497533)
1. Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease.
Sawyer JR; Tian E; Heuck CJ; Epstein J; Johann DJ; Swanson CM; Lukacs JL; Johnson M; Binz R; Boast A; Sammartino G; Usmani S; Zangari M; Waheed S; van Rhee F; Barlogie B
Blood; 2014 Apr; 123(16):2504-12. PubMed ID: 24497533
[TBL] [Abstract][Full Text] [Related]
2. An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome.
Sawyer JR; Tian E; Walker BA; Wardell C; Lukacs JL; Sammartino G; Bailey C; Schinke CD; Thanendrarajan S; Davies FE; Morgan GJ; Barlogie B; Zangari M; van Rhee F
Blood Cancer J; 2019 Aug; 9(8):62. PubMed ID: 31399558
[TBL] [Abstract][Full Text] [Related]
3. Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma.
Sawyer JR; Tian E; Heuck CJ; Johann DJ; Epstein J; Swanson CM; Lukacs JL; Binz RL; Johnson M; Sammartino G; Zangari M; Davies FE; van Rhee F; Morgan GJ; Barlogie B
Blood; 2015 Jun; 125(24):3756-9. PubMed ID: 25943786
[TBL] [Abstract][Full Text] [Related]
4. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.
Neben K; Jauch A; Hielscher T; Hillengass J; Lehners N; Seckinger A; Granzow M; Raab MS; Ho AD; Goldschmidt H; Hose D
J Clin Oncol; 2013 Dec; 31(34):4325-32. PubMed ID: 24145347
[TBL] [Abstract][Full Text] [Related]
5. Multiplex ligation-dependent probe amplification and fluorescence in situ hybridization are complementary techniques to detect cytogenetic abnormalities in multiple myeloma.
Alpar D; de Jong D; Holczer-Nagy Z; Kajtar B; Savola S; Jakso P; David M; Kosztolanyi S; Kereskai L; Pajor L; Szuhai K
Genes Chromosomes Cancer; 2013 Sep; 52(9):785-93. PubMed ID: 23720363
[TBL] [Abstract][Full Text] [Related]
6. Chromosome 1 abnormalities in multiple myeloma.
Marzin Y; Jamet D; Douet-Guilbert N; Morel F; Le Bris MJ; Morice P; Abgrall JF; Berthou C; De Braekeleer M
Anticancer Res; 2006; 26(2A):953-9. PubMed ID: 16619492
[TBL] [Abstract][Full Text] [Related]
7. Jumping translocations and high-risk myeloma.
Morgan GJ
Blood; 2014 Apr; 123(16):2442-3. PubMed ID: 24744247
[No Abstract] [Full Text] [Related]
8. Evidence for a novel mechanism for gene amplification in multiple myeloma: 1q12 pericentromeric heterochromatin mediates breakage-fusion-bridge cycles of a 1q12 approximately 23 amplicon.
Sawyer JR; Tian E; Thomas E; Koller M; Stangeby C; Sammartino G; Goosen L; Swanson C; Binz RL; Barlogie B; Shaughnessy J
Br J Haematol; 2009 Nov; 147(4):484-94. PubMed ID: 19744130
[TBL] [Abstract][Full Text] [Related]
9. Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma.
Merz M; Hielscher T; Seckinger A; Hose D; Mai EK; Raab MS; Goldschmidt H; Jauch A; Hillengass J
Am J Hematol; 2016 Nov; 91(11):E473-E477. PubMed ID: 27508939
[TBL] [Abstract][Full Text] [Related]
10. "Double-hit" chronic lymphocytic leukemia: An aggressive subgroup with 17p deletion and 8q24 gain.
Chapiro E; Lesty C; Gabillaud C; Durot E; Bouzy S; Armand M; Le Garff-Tavernier M; Bougacha N; Struski S; Bidet A; Laharanne E; Barin C; Veronese L; Prié N; Eclache V; Gaillard B; Michaux L; Lefebvre C; Gaillard JB; Terré C; Penther D; Bastard C; Nadal N; Fert-Ferrer S; Auger N; Godon C; Sutton L; Tournilhac O; Susin SA; Nguyen-Khac F;
Am J Hematol; 2018 Mar; 93(3):375-382. PubMed ID: 29194741
[TBL] [Abstract][Full Text] [Related]
11. 1q21 amplification with additional genetic abnormalities but not isolated 1q21 gain is a negative prognostic factor in newly diagnosed patients with multiple myeloma treated with thalidomide-based regimens.
Grzasko N; Hus M; Chocholska S; Pluta A; Hajek R; Dmoszynska A
Leuk Lymphoma; 2012 Dec; 53(12):2500-3. PubMed ID: 22497640
[No Abstract] [Full Text] [Related]
12. [Comparative study of genetic aberrations in human multiple myeloma cell lines and newly diagnosed MM by fluorescence in situ hybridization].
An G; Xie ZQ; Li CH; Li Q; Yi SH; Qiu LG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1505-10. PubMed ID: 21176360
[TBL] [Abstract][Full Text] [Related]
13. Genomic instability in multiple myeloma: evidence for jumping segmental duplications of chromosome arm 1q.
Sawyer JR; Tricot G; Lukacs JL; Binz RL; Tian E; Barlogie B; Shaughnessy J
Genes Chromosomes Cancer; 2005 Jan; 42(1):95-106. PubMed ID: 15472896
[TBL] [Abstract][Full Text] [Related]
14. Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma.
Sawyer JR; Lukacs JL; Thomas EL; Swanson CM; Goosen LS; Sammartino G; Gilliland JC; Munshi NC; Tricot G; Shaughnessy JD; Barlogie B
Br J Haematol; 2001 Jan; 112(1):167-74. PubMed ID: 11167798
[TBL] [Abstract][Full Text] [Related]
15. Detection of chromosome 13q deletions and IgH translocations in patients with multiple myeloma by FISH: comparison with karyotype analysis.
Chang H; Li D; Zhuang L; Nie E; Bouman D; Stewart AK; Chun K
Leuk Lymphoma; 2004 May; 45(5):965-9. PubMed ID: 15291356
[TBL] [Abstract][Full Text] [Related]
16. Different breakage-prone regions on chromosome 1 detected in t(11;14)-positive mantle cell lymphoma cell lines and multiple myeloma cell lines are associated with different tumor progression-related mechanisms.
Rudolph C; Liehr T; Steinemann D; Emura M; Daibata M; Matsuo Y; Emi N; Abe M; Lai R; Mrasek K; Claussen U; Schlegelberger B
Cytogenet Genome Res; 2006; 112(3-4):213-21. PubMed ID: 16484775
[TBL] [Abstract][Full Text] [Related]
17. Imaging flow cytometric detection of del(17p) in bone marrow and circulating plasma cells in multiple myeloma.
Mincherton TI; Lam SJ; Clarke SE; Hui HYL; Malherbe JAJ; Chuah HS; Sidiqi MH; Fuller KA; Erber WN
Int J Lab Hematol; 2024 Jun; 46(3):495-502. PubMed ID: 38379463
[TBL] [Abstract][Full Text] [Related]
18. The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma.
An G; Li Z; Tai YT; Acharya C; Li Q; Qin X; Yi S; Xu Y; Feng X; Li C; Zhao J; Shi L; Zang M; Deng S; Sui W; Hao M; Zou D; Zhao Y; Qi J; Cheng T; Ru K; Wang J; Anderson KC; Qiu L
Clin Cancer Res; 2015 May; 21(9):2148-56. PubMed ID: 25652456
[TBL] [Abstract][Full Text] [Related]
19. The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells.
López-Corral L; Gutiérrez NC; Vidriales MB; Mateos MV; Rasillo A; García-Sanz R; Paiva B; San Miguel JF
Clin Cancer Res; 2011 Apr; 17(7):1692-700. PubMed ID: 21325290
[TBL] [Abstract][Full Text] [Related]
20. Der(16)t(1;16)(q10;p10) in multiple myeloma: a new non-random abnormality that is frequently associated with Burkitt's-type translocations.
Mugneret F; Sidaner I; Favre B; Manone L; Maynadié M; Caillot D; Solary E
Leukemia; 1995 Feb; 9(2):277-81. PubMed ID: 7869764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
